β-blockers: A Long-standing Cornerstone of HFrEF Therapy
β-adrenergic blockade has been a mainstay of therapy in chronic heart failure with reduced ejection fraction (HFrEF) for more than two decades. β-blocker therapy is strongly supported across major consensus recommendation statements in patients with reduced EF and has consistently been shown to reduce mortality and HF-related hospitalisations in those who do not have contraindications.
Modern Medicine – Issue 5 2022
